Adenoma Detection Rates Calculated Using All Examinations Are Associated With Lower Risk for Postcolonoscopy Colorectal Cancer: Data From the New Hampshire Colonoscopy Registry.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
535 patients, a lower hazard for PCCRC (n = 178) was observed for ADR-A's ≥ 23%, as compared with ADR-A's <23% (reference) (23% to <29%: hazard ratio (HR) = 0.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
ADR-A may also increase precision of the calculated ADR. Endoscopists should strive for a higher ADR-A with 44% as an aspirational target.
[INTRODUCTION] We used New Hampshire Colonoscopy Registry data to examine the association between postcolonoscopy colorectal cancer (PCCRC) risk and an adenoma detection rate (ADR) which was calculate
- 표본수 (n) 178
- 95% CI 0.36-0.87
- HR 0.60
- 연구 설계 cohort study
APA
Anderson JC, Rex DK, et al. (2026). Adenoma Detection Rates Calculated Using All Examinations Are Associated With Lower Risk for Postcolonoscopy Colorectal Cancer: Data From the New Hampshire Colonoscopy Registry.. The American journal of gastroenterology, 121(2), 446-452. https://doi.org/10.14309/ajg.0000000000003488
MLA
Anderson JC, et al.. "Adenoma Detection Rates Calculated Using All Examinations Are Associated With Lower Risk for Postcolonoscopy Colorectal Cancer: Data From the New Hampshire Colonoscopy Registry.." The American journal of gastroenterology, vol. 121, no. 2, 2026, pp. 446-452.
PMID
40214109
Abstract
[INTRODUCTION] We used New Hampshire Colonoscopy Registry data to examine the association between postcolonoscopy colorectal cancer (PCCRC) risk and an adenoma detection rate (ADR) which was calculated using examinations with all indications, as compared with ADR restricted to only screening examinations.
[METHODS] Our cohort study included New Hampshire Colonoscopy Registry patients with an index examination and at least 1 follow-up event, either a colonoscopy or a CRC diagnosis. Our outcome, PCCRC, was any CRC diagnosed ≥6 months after an index examination. The exposure variable was endoscopist-specific all-examination ADR (ADR-A), calculated for all indications, divided into quintiles. We also compared the ADR-A with a screening ADR (ADR-S). Cox regression was used to model the hazard of PCCRC on ADR, controlling for age, sex, and other covariates.
[RESULTS] In 32,535 patients, a lower hazard for PCCRC (n = 178) was observed for ADR-A's ≥ 23%, as compared with ADR-A's <23% (reference) (23% to <29%: hazard ratio (HR) = 0.56, 95% CI: 0.36-0.87; 29% to <34%: HR = 0.60, 95% CI: 0.38-0.94; 34% to <44%: HR = 0.43, 95% CI: 0.29-0.65; and ≥44%: HR = 0.32, 95% CI: 0.16-0.63). The highest quartile of ADR-A (42%+) (HR = 0.41, 95% CI: 0.23-0.75) had a similar protection from PCCRC as the highest quartile of ADR-S (35%+) (HR = 0.38, 95% CI: 0.21-0.70). We observed 95% CIs for ADR's were 28% narrower (median = 0.72; interquartile range (IQR): 0.10) for endoscopists when using ADR-A vs ADR-S.
[DISCUSSION] Our data demonstrating lower PCCRC risk in examinations performed by endoscopists with higher ADR's calculated with all examinations help to validate ADR-A as a quality measure. ADR-A may also increase precision of the calculated ADR. Endoscopists should strive for a higher ADR-A with 44% as an aspirational target.
[METHODS] Our cohort study included New Hampshire Colonoscopy Registry patients with an index examination and at least 1 follow-up event, either a colonoscopy or a CRC diagnosis. Our outcome, PCCRC, was any CRC diagnosed ≥6 months after an index examination. The exposure variable was endoscopist-specific all-examination ADR (ADR-A), calculated for all indications, divided into quintiles. We also compared the ADR-A with a screening ADR (ADR-S). Cox regression was used to model the hazard of PCCRC on ADR, controlling for age, sex, and other covariates.
[RESULTS] In 32,535 patients, a lower hazard for PCCRC (n = 178) was observed for ADR-A's ≥ 23%, as compared with ADR-A's <23% (reference) (23% to <29%: hazard ratio (HR) = 0.56, 95% CI: 0.36-0.87; 29% to <34%: HR = 0.60, 95% CI: 0.38-0.94; 34% to <44%: HR = 0.43, 95% CI: 0.29-0.65; and ≥44%: HR = 0.32, 95% CI: 0.16-0.63). The highest quartile of ADR-A (42%+) (HR = 0.41, 95% CI: 0.23-0.75) had a similar protection from PCCRC as the highest quartile of ADR-S (35%+) (HR = 0.38, 95% CI: 0.21-0.70). We observed 95% CIs for ADR's were 28% narrower (median = 0.72; interquartile range (IQR): 0.10) for endoscopists when using ADR-A vs ADR-S.
[DISCUSSION] Our data demonstrating lower PCCRC risk in examinations performed by endoscopists with higher ADR's calculated with all examinations help to validate ADR-A as a quality measure. ADR-A may also increase precision of the calculated ADR. Endoscopists should strive for a higher ADR-A with 44% as an aspirational target.
MeSH Terms
Humans; Colonoscopy; Male; Female; Colorectal Neoplasms; Adenoma; Registries; Middle Aged; New Hampshire; Aged; Early Detection of Cancer; Proportional Hazards Models; Cohort Studies